The Celconta Group is a biotechnology company integrating cell storage, research and development, production and promotion. With "precision medicine" as the core, the Group has built industrial clusters such as cell cryopreservation, cell medicine and development, and regenerative medicine, etc. Its business covers the upper, middle and lower reaches of the cell industry, establishing an industry with a full production chain. The group owns 3"national high-tech enterprises" .
Shenzhen Celconta Life Science Co., Ltd.
Shenzhen Celconta Life Science Co., Ltd. (referred to as "First Condor Life"), established in March 2020, is a biopharmaceutical company focusing on the research and industrialization of cell immunotherapy for solid tumors.Thecompany takes the independent research and development of CAR-T products as its forerunner, and simultaneously taps into international cutting-edge technologies such as CAR-NK and CAR-iT. The company has developed three technology platforms with independent intellectual property rights: Trans-CAR®, Boost-CAR®, and R-Star, and has carried out clinical research on solid tumor CAR-T targeting CLDN18.2 and GUCY2C targets in a number of Grade A tertiary hospitals.